Loading patent…
AssigneeMeda Pharmaceuticals Inc.
InventorsGul Balwani, Harry J. Sacks, Bryan A. Roecklein, Benjamin Johns
Estimating the term…
The present invention provides compositions comprising carisoprodol or pharmaceutically acceptable salts, esters or derivatives thereof. In certain embodiments, the invention provides pharmaceutical compositions comprising the skeletal muscle relaxant carisoprodol and one or more additional active agents, such as one or more nonsteroidal antiinflammatory drugs (NSAIDs). The invention further provides methods of use of such compositions in preventing, alleviating and/or treating musculoskeletal pain, muscle spasms, or other non-malignant painful conditions including methods in which the circulating levels of the active pharmaceutical form of carisoprodol are controlled by use of extended- or controlled-release formulations or by strict control of dosage regimen, so as to reduce the level of somnolence observed with other muscle relaxant compositions.
A controlled release pharmaceutical formulation suitable for oral administration, comprising carisoprodol or a pharmaceutically acceptable, salt or ester thereof, and a pharmaceutically acceptable matrix adapted to provide a controlled release of carisoprodol or a pharmaceutically acceptable, salt or ester thereof upon oral administration,
A pharmaceutical composition comprising carisoprodol, or a pharmaceutically acceptable, salt or ester thereof, and one or more additional active agents selected from the group consisting of non-aspirin NSAID, one or more muscle relaxing compounds, one or more anxiolytic compounds, one or more narcotic analgesics, one or more non-narcotic analgesics, one or more anticonvulsants, one or more antipsychotics, and one or more antidepressants, said composition having a dissolution rate in vitro when measured using Apparatus 2 (paddle) described in USP 30 at 65 rpm in 1000 ml of 0.1N hydrochloric acid from 0 hours to 12 hours of dissolution at 37.0±0.5° C. and using high performance liquid chromatography (HPLC) for quantification:
A pharmaceutical composition for controlled onset and extended release of carisoprodol, said composition comprising:
A pharmaceutical composition comprising carisoprodol, or a pharmaceutically acceptable, salt or ester thereof wherein said carisoprodol or a pharmaceutically acceptable salt or ester thereof has a particle size such that either (a) about 100% of the particles have an average size of less than about 50 microns, or (b) greater than about 40% of the particles are about 250 microns or greater said composition having a dissolution rate in vitro when measured using Apparatus 2 (paddle) described in USP 30 at 65 rpm in 1000 ml of 0.1N hydrochloric acid from 0 hours to 12 hours of dissolution at 37.0±0.5° C. and using high performance liquid chromatography (HPLC) for quantification:
A pharmaceutical composition comprising:
Dependencies are inferred from the claim text.